摘要
目的探讨脂肪肝对于聚乙二醇干扰素α和阿德福韦酯联合治疗慢性乙肝的疗效影响。方法选择2013年4月—2016年3月本院收治的慢性乙肝患者46例患者进行研究,均予以聚乙二醇干扰素α联合阿德福韦酯治疗,并分为对照组(未合并脂肪肝)20例和观察组(合并脂肪肝)26例,对比2组疗效。结果 2组的HBe Ag转换、病毒学应答、生化学应答率对比差异无统计学意义(P均>0.05)。结论脂肪肝不会影响到聚乙二醇干扰素α联合阿德福韦酯治疗慢性乙肝的疗效。
Objective To investigate the impact of fatty liver on the clinical efficacy of pegylated interferon α and adefovir dipivoxil in the treatment of chronic hepatitis B patients. Methods A total of 46 chronic hepatitis B inpatients were selected as the study objects from April 2013 to March 2016, and they were treated with pegylated interferon α combined with adefovir dipivoxil. These patients were divided into a control group（non-combined with fatty liver, 20 cases） and an observation group（combined with fatty liver, 26 cases）, and the clinical effects were investigated and the results were compared between two groups. Results There were no significant differences between the two groups in the HBe Ag conversion, virological response, and biochemical response rate（P0.05）. Conclusion Fatty liver does not affect the clinical efficacy of pegylated interferon α and adefovir dipivoxil in the treatment of chronic hepatitis B.
作者
张丽丽
ZHANG Li-li;Taizhou People＇s Hospital;
出处
《中国校医》
2016年第12期931-932,共2页
Chinese Journal of School Doctor
